Clinical Co-Development

Abingworth Clinical Co-Development (ACCD) Financing

We take 100% of the financial risk. Success payments are due only if the drug is approved and these may include a royalty component. The cost for such funding is targeted to be competitive with internal risk-adjusted costs.

We have an Abingworth Direct Financing option aimed at funding development programs, which are executed by companies independently. Our co-development portfolio companies Launch Tx, SFJ and Avillion bring operational expertise, in addition to capital, to facilitate clinical trial execution globally thereby increasing the speed and quality of the trials.

Addressing Biopharma Needs

ACCD financing enables companies to:

• Access development funding while minimising EPS impact and avoiding costly equity dilution
• Expand pipeline of development programs via life cycle management and geographic expansion
• Leverage the option of global clinical and regulatory teams to execute speedy and high-quality trials

Target Assets

Assets will typically be Phase 3 ready or pivotal, with a high probability of reaching approval and successful commercialisation within a few years. The assets can be new molecular entities (NMEs) or already approved products being trialled in new indications. Single or multiple assets can be considered for global or regional development programs.

Size and Timing

Investment size is typically upwards of $30m. We offer flexible financing solutions across the capital structure, and work with companies to evaluate a combination of equity and CCD financing where appropriate. Diligence is rapid, leading to an initial go/no-go decision in weeks.